CAN-2409
Non-Small Cell Lung Cancer (NSCLC)
Key Facts
About Candel Therapeutics
Candel Therapeutics is a clinical-stage biotech focused on developing multimodal oncolytic viral immunotherapies for cancer. Its mission is to leverage engineered adenovirus and herpes simplex virus (HSV) platforms to induce immunogenic cell death and train the immune system to fight tumors. The company's strategy centers on advancing its lead candidates, CAN-2409 and CAN-3110, through late-stage trials in non-small cell lung cancer (NSCLC), prostate cancer, pancreatic cancer, and brain cancer, aiming to generate pivotal data for regulatory submissions. As a publicly traded, pre-revenue entity, Candel's near-term value is tied to clinical milestones and partnership potential in the competitive immuno-oncology landscape.
View full company profileAbout Candel Therapeutics
Candel Therapeutics is a clinical-stage biotech focused on developing multimodal oncolytic viral immunotherapies for cancer. Its mission is to leverage engineered adenovirus and herpes simplex virus (HSV) platforms to induce immunogenic cell death and train the immune system to fight tumors. The company's strategy centers on advancing its lead candidates, CAN-2409 and CAN-3110, through late-stage trials in non-small cell lung cancer (NSCLC), prostate cancer, pancreatic cancer, and brain cancer, aiming to generate pivotal data for regulatory submissions. As a publicly traded, pre-revenue entity, Candel's near-term value is tied to clinical milestones and partnership potential in the competitive immuno-oncology landscape.
View full company profileAbout Candel Therapeutics
Candel Therapeutics is a clinical-stage biotech focused on developing multimodal oncolytic viral immunotherapies for cancer. Its mission is to leverage engineered adenovirus and herpes simplex virus (HSV) platforms to induce immunogenic cell death and train the immune system to fight tumors. The company's strategy centers on advancing its lead candidates, CAN-2409 and CAN-3110, through late-stage trials in non-small cell lung cancer (NSCLC), prostate cancer, pancreatic cancer, and brain cancer, aiming to generate pivotal data for regulatory submissions. As a publicly traded, pre-revenue entity, Candel's near-term value is tied to clinical milestones and partnership potential in the competitive immuno-oncology landscape.
View full company profileTherapeutic Areas
Other Non-Small Cell Lung Cancer (NSCLC) Drugs
| Drug | Company | Phase |
|---|---|---|
| LW-02 Immunopheresis | Immunicom | Phase 2 |
| Idylla EGFR Mutation Assay | Biocartis | Approved |
| ABD-3001 | Advanced Biodesign | Phase 1 |
| Macrocyclic OMNI-EGFR Inhibitor | BlossomHill Therapeutics | Phase 1 |
| TUMORIN Clinical Trial | Nilogen Oncosystems | N/A (Diagnostic Validation) |
| Membrex™ | Metaclipse Therapeutics | Pre-clinical |
| Lazertinib (Leclaza) | Genosco | Approved |
| IPH5201 (anti-CD39 mAb) | Orega Biotech | Phase 2 |
| Platin-DRP® | Chosa Oncology | Validation |
| Undisclosed RNA Immunotherapy | Epitopea | Pre-clinical |
| Aspyre Clinical Test for Lung | Biofidelity | Commercial |
| EGFR Mutation Detection Assay | Stilla Technologies | Assay Development/Validation |